Ultragenyx Pharmaceutical develops and commercializes treatments for rare and ultra-rare genetic diseases, including metabolic, bone, and gene-therapy programs.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| Paul Tudor Jones / Tudor | 61 | New buy | 12,600 | $189,378 | 0.0% |
| Steve Cohen / Point72 | 75 | New buy | 844,410 | $12,691,482 | 0.0% |
| Bridgewater | 55 | New buy | 57,052 | $857,492 | 0.0% |
| Trade date | Who | Type | Amount | |
|---|---|---|---|---|
| 2026-09-29 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-03-03 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
| 2026-02-18 | Gilbert Cisneros CA31 | BUY | $1,001 - $15,000 | PTR |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-11-17.